Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-1019T in Children 2 to <6 Years
NCT06666179Phase 1Withdrawn
- Sponsor
- Clover Biopharmaceuticals
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCB-1019 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Proportion of participants with solicited Adverse Events at 7 days, Proportion of participants with unsolicited Adverse Events at 28 days and 1 more. Planned start Oct 2025; status: withdrawn.
02
Drugs
SCB-1019
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06666179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666179.